Global Targeted PSMA Radionuclide Drug Conjugates Market Growth (Status and Outlook) 2026-2032
The global Targeted PSMA Radionuclide Drug Conjugates market size is predicted to grow from US$ 1951 million in 2025 to US$ 3381 million in 2032; it is expected to grow at a CAGR of 7.9% from 2026 to 2032.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
LPI (LP Information)' newest research report, the ?Targeted PSMA Radionuclide Drug Conjugates Industry Forecast? looks at past sales and reviews total world Targeted PSMA Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted PSMA Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted PSMA Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted PSMA Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted PSMA Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted PSMA Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted PSMA Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted PSMA Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted PSMA Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted PSMA Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
LPI (LP Information)' newest research report, the ?Targeted PSMA Radionuclide Drug Conjugates Industry Forecast? looks at past sales and reviews total world Targeted PSMA Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted PSMA Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted PSMA Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted PSMA Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted PSMA Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted PSMA Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted PSMA Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted PSMA Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted PSMA Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted PSMA Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Monotherapy Products
- Combination Therapy Products
- Beta-emitting
- Alpha-emitting
- Other
- Small-molecule
- Antibody-based
- Other
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Curium
- Telix Pharmaceuticals
- Lantheus
- Fusion Pharmaceuticals
- Blue Earth Therapeutics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size (2021-2032)
2.1.2 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted PSMA Radionuclide Drug Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Targeted PSMA Radionuclide Drug Conjugates Segment by Type
2.2.1 Monotherapy Products
2.2.2 Combination Therapy Products
2.2.3 Targeted PSMA Radionuclide Drug Conjugates Market Size by Type
2.2.3.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
2.3 Targeted PSMA Radionuclide Drug Conjugates Segment by Radionuclide Type
2.3.1 Beta-emitting
2.3.2 Alpha-emitting
2.3.3 Other
2.3.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type
2.3.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
2.4 Targeted PSMA Radionuclide Drug Conjugates Segment by Targeting Vector Type
2.4.1 Small-molecule
2.4.2 Antibody-based
2.4.3 Other
2.4.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type
2.4.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032)
2.4.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
2.5 Targeted PSMA Radionuclide Drug Conjugates Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Application
2.5.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
3 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE BY PLAYER
3.1 Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Player
3.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.1.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Targeted PSMA Radionuclide Drug Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES BY REGION
4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026)
4.2 Global Targeted PSMA Radionuclide Drug Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.4 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.5 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
5.2 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026)
6.2 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
6.3 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
7.2 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
7.3 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates by Region (2021-2026)
8.2 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET FORECAST
10.1 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.3 APAC Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.4 Europe Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.5 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2 Americas Targeted PSMA Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.2 Canada Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.3 Mexico Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.4 Brazil Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3 APAC Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.3.1 China Targeted PSMA Radionuclide Drug Conjugates Market Forecast
10.3.2 Japan Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.3 Korea Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.4 Southeast Asia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.5 India Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.6 Australia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4 Europe Targeted PSMA Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.2 France Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.3 UK Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.4 Italy Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.5 Russia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.2 South Africa Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.3 Israel Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.4 Turkey Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.6 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Type (2027-2032)
10.7 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted PSMA Radionuclide Drug Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Curium
11.2.1 Curium Company Information
11.2.2 Curium Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Curium Main Business Overview
11.2.5 Curium Latest Developments
11.3 Telix Pharmaceuticals
11.3.1 Telix Pharmaceuticals Company Information
11.3.2 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Telix Pharmaceuticals Main Business Overview
11.3.5 Telix Pharmaceuticals Latest Developments
11.4 Lantheus
11.4.1 Lantheus Company Information
11.4.2 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Lantheus Main Business Overview
11.4.5 Lantheus Latest Developments
11.5 Fusion Pharmaceuticals
11.5.1 Fusion Pharmaceuticals Company Information
11.5.2 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Fusion Pharmaceuticals Main Business Overview
11.5.5 Fusion Pharmaceuticals Latest Developments
11.6 Blue Earth Therapeutics
11.6.1 Blue Earth Therapeutics Company Information
11.6.2 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Blue Earth Therapeutics Main Business Overview
11.6.5 Blue Earth Therapeutics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size (2021-2032)
2.1.2 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted PSMA Radionuclide Drug Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Targeted PSMA Radionuclide Drug Conjugates Segment by Type
2.2.1 Monotherapy Products
2.2.2 Combination Therapy Products
2.2.3 Targeted PSMA Radionuclide Drug Conjugates Market Size by Type
2.2.3.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
2.3 Targeted PSMA Radionuclide Drug Conjugates Segment by Radionuclide Type
2.3.1 Beta-emitting
2.3.2 Alpha-emitting
2.3.3 Other
2.3.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type
2.3.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
2.4 Targeted PSMA Radionuclide Drug Conjugates Segment by Targeting Vector Type
2.4.1 Small-molecule
2.4.2 Antibody-based
2.4.3 Other
2.4.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type
2.4.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032)
2.4.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
2.5 Targeted PSMA Radionuclide Drug Conjugates Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Targeted PSMA Radionuclide Drug Conjugates Market Size by Application
2.5.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
3 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE BY PLAYER
3.1 Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Player
3.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.1.2 Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Targeted PSMA Radionuclide Drug Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES BY REGION
4.1 Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026)
4.2 Global Targeted PSMA Radionuclide Drug Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.4 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.5 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
5.2 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3 Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026)
6.2 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
6.3 APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
7.2 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
7.3 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates by Region (2021-2026)
8.2 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET FORECAST
10.1 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.1 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.3 APAC Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.4 Europe Targeted PSMA Radionuclide Drug Conjugates Forecast
10.1.5 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2 Americas Targeted PSMA Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.2 Canada Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.3 Mexico Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.2.4 Brazil Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3 APAC Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.3.1 China Targeted PSMA Radionuclide Drug Conjugates Market Forecast
10.3.2 Japan Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.3 Korea Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.4 Southeast Asia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.5 India Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.3.6 Australia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4 Europe Targeted PSMA Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.2 France Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.3 UK Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.4 Italy Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.4.5 Russia Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.2 South Africa Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.3 Israel Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.5.4 Turkey Market Targeted PSMA Radionuclide Drug Conjugates Forecast
10.6 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Type (2027-2032)
10.7 Global Targeted PSMA Radionuclide Drug Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted PSMA Radionuclide Drug Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Curium
11.2.1 Curium Company Information
11.2.2 Curium Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Curium Main Business Overview
11.2.5 Curium Latest Developments
11.3 Telix Pharmaceuticals
11.3.1 Telix Pharmaceuticals Company Information
11.3.2 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Telix Pharmaceuticals Main Business Overview
11.3.5 Telix Pharmaceuticals Latest Developments
11.4 Lantheus
11.4.1 Lantheus Company Information
11.4.2 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Lantheus Main Business Overview
11.4.5 Lantheus Latest Developments
11.5 Fusion Pharmaceuticals
11.5.1 Fusion Pharmaceuticals Company Information
11.5.2 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Fusion Pharmaceuticals Main Business Overview
11.5.5 Fusion Pharmaceuticals Latest Developments
11.6 Blue Earth Therapeutics
11.6.1 Blue Earth Therapeutics Company Information
11.6.2 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product Offered
11.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Blue Earth Therapeutics Main Business Overview
11.6.5 Blue Earth Therapeutics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted PSMA Radionuclide Drug Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monotherapy Products
Table 4. Major Players of Combination Therapy Products
Table 5. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Beta-emitting
Table 9. Major Players of Alpha-emitting
Table 10. Major Players of Other
Table 11. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026) & ($ millions)
Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
Table 14. Major Players of Small-molecule
Table 15. Major Players of Antibody-based
Table 16. Major Players of Other
Table 17. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026) & ($ millions)
Table 19. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
Table 20. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 23. Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
Table 25. Targeted PSMA Radionuclide Drug Conjugates Key Players Head office and Products Offered
Table 26. Targeted PSMA Radionuclide Drug Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 31. Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 35. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 37. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 39. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 41. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 45. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Targeted PSMA Radionuclide Drug Conjugates
Table 51. Key Market Challenges & Risks of Targeted PSMA Radionuclide Drug Conjugates
Table 52. Key Industry Trends of Targeted PSMA Radionuclide Drug Conjugates
Table 53. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novartis Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 58. Novartis Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 59. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novartis Main Business
Table 61. Novartis Latest Developments
Table 62. Curium Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 63. Curium Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 64. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Curium Main Business
Table 66. Curium Latest Developments
Table 67. Telix Pharmaceuticals Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 68. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 69. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Telix Pharmaceuticals Main Business
Table 71. Telix Pharmaceuticals Latest Developments
Table 72. Lantheus Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 73. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 74. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Lantheus Main Business
Table 76. Lantheus Latest Developments
Table 77. Fusion Pharmaceuticals Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 78. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 79. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Fusion Pharmaceuticals Main Business
Table 81. Fusion Pharmaceuticals Latest Developments
Table 82. Blue Earth Therapeutics Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 83. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 84. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Blue Earth Therapeutics Main Business
Table 86. Blue Earth Therapeutics Latest Developments
Table 1. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted PSMA Radionuclide Drug Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monotherapy Products
Table 4. Major Players of Combination Therapy Products
Table 5. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Beta-emitting
Table 9. Major Players of Alpha-emitting
Table 10. Major Players of Other
Table 11. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026) & ($ millions)
Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
Table 14. Major Players of Small-molecule
Table 15. Major Players of Antibody-based
Table 16. Major Players of Other
Table 17. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026) & ($ millions)
Table 19. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
Table 20. Targeted PSMA Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 23. Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
Table 25. Targeted PSMA Radionuclide Drug Conjugates Key Players Head office and Products Offered
Table 26. Targeted PSMA Radionuclide Drug Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 31. Global Targeted PSMA Radionuclide Drug Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 35. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 37. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 39. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 41. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 45. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Targeted PSMA Radionuclide Drug Conjugates
Table 51. Key Market Challenges & Risks of Targeted PSMA Radionuclide Drug Conjugates
Table 52. Key Industry Trends of Targeted PSMA Radionuclide Drug Conjugates
Table 53. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novartis Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 58. Novartis Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 59. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novartis Main Business
Table 61. Novartis Latest Developments
Table 62. Curium Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 63. Curium Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 64. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Curium Main Business
Table 66. Curium Latest Developments
Table 67. Telix Pharmaceuticals Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 68. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 69. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Telix Pharmaceuticals Main Business
Table 71. Telix Pharmaceuticals Latest Developments
Table 72. Lantheus Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 73. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 74. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Lantheus Main Business
Table 76. Lantheus Latest Developments
Table 77. Fusion Pharmaceuticals Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 78. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 79. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Fusion Pharmaceuticals Main Business
Table 81. Fusion Pharmaceuticals Latest Developments
Table 82. Blue Earth Therapeutics Details, Company Type, Targeted PSMA Radionuclide Drug Conjugates Area Served and Its Competitors
Table 83. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product Offered
Table 84. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Blue Earth Therapeutics Main Business
Table 86. Blue Earth Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted PSMA Radionuclide Drug Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 10. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 11. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 12. Targeted PSMA Radionuclide Drug Conjugates in Hospital
Figure 13. Global Targeted PSMA Radionuclide Drug Conjugates Market: Hospital (2021-2026) & ($ millions)
Figure 14. Targeted PSMA Radionuclide Drug Conjugates in Clinic
Figure 15. Global Targeted PSMA Radionuclide Drug Conjugates Market: Clinic (2021-2026) & ($ millions)
Figure 16. Targeted PSMA Radionuclide Drug Conjugates in Others
Figure 17. Global Targeted PSMA Radionuclide Drug Conjugates Market: Others (2021-2026) & ($ millions)
Figure 18. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 19. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player in 2025
Figure 20. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 21. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 22. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 23. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 25. Americas Targeted PSMA Radionuclide Drug Conjugates Value Market Share by Country in 2025
Figure 26. United States Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region in 2025
Figure 31. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 32. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 33. China Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 37. India Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country in 2025
Figure 40. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 41. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 42. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. France Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 56. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 59. United States Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 63. China Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Korea Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 67. India Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 70. France Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 71. UK Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Egypt Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 75. South Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 76. Israel Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 77. Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 78. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted PSMA Radionuclide Drug Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 10. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 11. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 12. Targeted PSMA Radionuclide Drug Conjugates in Hospital
Figure 13. Global Targeted PSMA Radionuclide Drug Conjugates Market: Hospital (2021-2026) & ($ millions)
Figure 14. Targeted PSMA Radionuclide Drug Conjugates in Clinic
Figure 15. Global Targeted PSMA Radionuclide Drug Conjugates Market: Clinic (2021-2026) & ($ millions)
Figure 16. Targeted PSMA Radionuclide Drug Conjugates in Others
Figure 17. Global Targeted PSMA Radionuclide Drug Conjugates Market: Others (2021-2026) & ($ millions)
Figure 18. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 19. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Player in 2025
Figure 20. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 21. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 22. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 23. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 25. Americas Targeted PSMA Radionuclide Drug Conjugates Value Market Share by Country in 2025
Figure 26. United States Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region in 2025
Figure 31. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 32. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 33. China Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 37. India Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Country in 2025
Figure 40. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 41. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 42. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. France Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Targeted PSMA Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 56. APAC Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 59. United States Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 63. China Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Korea Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 67. India Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 70. France Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 71. UK Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Egypt Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 75. South Africa Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 76. Israel Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 77. Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 78. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Targeted PSMA Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
